Amgen Inc.

Amgen Sf, LLC

Zice Fu

Julio Cesar Medina

Jonathan B Houze

Xiaoqi Chen

Zhihua Ma

Paul John Dransfield

Jeffrey Thomas Mihalic

Xiaohui Du

Vatee Pattaropong

Julie Anne Heath

David John Kopecky

Xiaodong Wang

Jeffrey Deignan

Richard V Connors

Steven H Olson

Ning Chen

Su-Jen Lai

Nobuko Nishimura

Lawrence R McGee

Matthew R Kaller

Jiwen Liu

Daniel B Horne

Alan C Cheng

Mikkel V Debenedetto

Gayathri Swaminath

Frank Kayser

Kevin Chao Yang

Ted Charles Judd

Simon J Hedley

Wen-Chen Yeh

Yingcai Wang

Yinhong Chen

Aarif Yusuf Khakoo

Robert P Farrell

Ming Yu

XianYun Jiao

SuJen Lai

Wang Shen

Michael G Johnson

Jason A Duquette

Darin J Gustin

An-Rong Li

Michael J Schmitt

Marc Vimolratana

Hilary Plake Beck

Todd J Kohn

James S Harvey

Sean P Brown

Zhongyu Wang

Jinqian Liu

Philippe Bergeron

Jiang Zhu

Daqing Sun

Liusheng Zhu

Xuelei Yan

Dustin L McMinn

Rajiv Sharma

Yosup Rew

Leping Li

Felix Gonzalez Lopez De Turiso

Jonathan Dante Low

Brian M Fox

Michael D Bartberger

John Eksterowicz

Brian Stuart Lucas

Ana Zurisadai Gonzalez Buenrostro

Zhihong Li

Joel McIntosh

Lars V Heumann

Mike Elias Lizarzaburu

Jiasheng Fu

Xian Yun Jiao

Yihong Li

Michael W Gribble, Jr

Xin Huang

Benjamin Fisher

Philip M Roveto

Jennifer Rebecca Allen

Matthew Irvine Brown

Qingyian Liu

Longbin Liu

Liping H Pettus

Yasuyuki Ogawa

Michael J Frohn

Jian Luo

Xiaolin Hao

Aaron C Siegmund

Matthew Paul Bourbeau

James A Brown

Wenyuan Qian

Hui Tian

Kevin Yang

Sarah Lively

Zhaodan Cao

Satoshi Shibuya

Jie Zhang

Narihiro Toda

YuMei Xiong

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: 

1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Bromotriazole intermediates are useful in the synthesis of agonists of the APH receptor. Such compounds include those selected from 

Bromotriazole intermediates

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers have the following structure and are useful compounds in preparing small molecule agonists of the APJ Receptor: where the definitions of the variables are provided herein.

Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor

Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.

Methods of treating heart failure

Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heterocyclic triazole compounds as agonists of the APJ receptor

Compounds of Formula VII, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula VII have the following structure: where the definitions of the variables are provided herein.

Intermediates for preparing triazole agonists of the APJ receptor

Methods of preparing compounds of Formula VI, salts thereof, tautomers thereof, or salts of the tautomers include cyclizing compounds of Formula V, salts thereof, tautomers thereof, or salts of the tautomers. Compounds of Formula VI and Formula V have the following structures: where the definitions of the variables are provided herein.

Methods for preparing triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula V have the following structure: where the definitions of the variables are provided herein.

The present invention provides MDM2 inhibitor compounds of Formula I, 

Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer

Growing community of inventors

Foster City, CA, United States of America

Zice Fu